Reviewing therapy with radioisotopes for pain bone metastasis and its possible evolution

Autores/as

  • Daniel Coiro Silva Santa Casa Bahia ,
  • Roberto Jose Meyer Nascimento ,

DOI:

https://doi.org/10.15392/bjrs.v10i2.2011

Palabras clave:

Radiopharmaceuticals. Radioisotope. Metastasis. Bone

Resumen

Introduction: The therapy with radioisotopes is widely used, its beginnings were focused on thyroid pathologies treatments.  Over the years, the radiopharmaceuticals and/or radioisotopes have had their usage increased, to be used on painful bone metastasis. Material and Methods: A bibliographic search was conducted in the major health Science basis to evaluate what the therapies have to offer for patients in this condition. Results: Currently there are only two available materials in Brazil, the Sm153 that is national production, and Ra223, that is imported. Outside Brazil we can find a variety of materials that have already been approved by the Sanitary Organization in other countries, even though we are not authorized to use them due to Brazilian Regulation and production issues. Conclusion: Besides the diversity of materials that could be used, dosimetry systems must be implemented in order to have a more efficient treatment and to have an accurate administrated activities to patients.

 

Descargas

Los datos de descarga aún no están disponibles.

Referencias

V. Ralph McCready. Radioiodine – the success story of Nuclear Medicine. Eur J Nucl Med Mol Imaging (2017) 44:179–182

Luis Costa & Xavier Badia & Edward Chow et all. Impact of skeletal complications on patients’ quality of life, mobility, and functional Independence. Support Care Cancer (2008) 16:879–889

Narendra Nair, Relative Efficacy of 32P and 89Sr in Palliation in Skeletal Metastases. J NucI Med1999.40:256 a 261

Neeta Pandit-Taskar, Steven M. Larson et all, Bone-Seeking Radiopharmaceuticals for Treatment of Osseous Metastases, Part 1: Therapy with 223Ra-Dichloride. J Nucl Med 2014; 55:268–274

Hélène Kolesnikov-Gauthier, Nathalie Lemoine, Emmanuelle Tresch-Bruneel et all. Efficacy and safety of 153Sm-EDTMP as treatment of painful bone metastasis: a large single-center study. Support Care Cancer DOI 10.1007/s00520-017-3885-3.

Ajit S. Shinto, Madhava B. Mallia, Mythili Kameswaran, et all. Clinical utility of 188Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies. World J Nucl Med. 2018 Oct-Dec; 17(4): 228–235.

Jörgen Elgqvist,SofiaFrost, Jean-Pierre Pouget,PerAlbertsson. The potential and hurdles of targeted alpha therapy – clinical trials and beyond. Frontiers in Oncology January 2014 | Volume 3 | Article 324

Mareike Roscher , Gábor Bakos and Martina Benešová. Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management. Pharmaceuticals 2020, 13, 76.

G.B. Saha, Fundamentals of Nuclear Pharmacy, Springer International Publishing AG 2018 (paperback).

Ballinger JR. Theranostic radiopharmaceuticals: established agents in current use. Br J Radiol 2018; 91

Maria E. Lyra, Maria Andreou, Antonios Georgantzoglou et all. Radionuclides Used in Nuclear Medicine Therapy – From Production to Dosimetry. Current Medical Imaging Reviews, 2013, 9, 51-75 51.

Hojjat Ahmadzadehfar, MD, MSc , Markus Essler, MD , Kambiz Rahbar, MD , et all Radionuclide Therapy for bone metastases utility of scintigraphy and PET imaging for treatment planning. PET Clin. 2018; 13:491–503).

Joon Young Choi. Treatment of Bone Metastasis with Bone-Targeting Radiopharmaceuticals. Nuclear Medicine and Molecular Imaging (2018) 52:200–207

George Sgouros , Lisa Bodei , Michael R. McDevitt et all. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 19, 819 (2020)

Mareike Roscher, Gábor Bakos, Martina Benešová. Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management. Pharmaceuticals 020, 13, 76;

Stephen A. Graves, PhD, and Robert F. Hobbs, PhD. Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy. Semin Radiat Oncol 31:37−44.2020

Ashutosh Dash, Tapas Das, and Furn F. (Russ) Knapp Jr. Targeted Radionuclide Therapy of Painful Bone Metastases: Past De- velopments, Current Status, Recent Advances and Future Directions. Current Medicinal Chemistry, 2020, 27, 3187-3249

Diretrizes básicas de proteção radiológica. Norma CNENNN3.01 Resolução 164/14Março/2014

Requisitos de segurança e proteção radiológica para serviços de medicina nuclear. Norma CNEN NN 3.05 Resolução CNEN 159/13 dez./2013

Resolução-RDC No 64, de 18 de dezembro de 2009. ANVISA

Publicado

2022-06-13

Número

Sección

Review Articles

Cómo citar

Reviewing therapy with radioisotopes for pain bone metastasis and its possible evolution. Brazilian Journal of Radiation Sciences (BJRS), Rio de Janeiro, Brazil, v. 10, n. 2, 2022. DOI: 10.15392/bjrs.v10i2.2011. Disponível em: https://bjrs.org.br/revista/index.php/REVISTA/article/view/2011. Acesso em: 17 jul. 2025.